ABBV-547
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 23, 2025
AbbVie Completes Acquisition of Nimble Therapeutics
(PRNewswire)
- "AbbVie...announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis."
M&A • Psoriasis
1 to 1
Of
1
Go to page
1